ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2011
Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis.
Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Tumor-platelet cross talk in cancer: mechanisms, thrombotic risk, and translational opportunities.Blood advances · 2026Review
- Day + 100 bone marrow megakaryocyte count predicts transplant outcome in patients with high-risk myelodysplastic syndrome and acute leukemia.Journal of hematopathology · 2025Article
- Multiple influence of immune cells in the bone metastatic cancer microenvironment on tumors.Frontiers in immunology · 2024Review
- Role of Nitric Oxide in Megakaryocyte Function.International journal of molecular sciences · 2023Review
- S100 Calcium-Binding Protein P Secreted from Megakaryocytes Promotes Osteoclast Maturation.International journal of molecular sciences · 2021Article
- Bone marrow niches in the regulation of bone metastasis.British journal of cancer · 2021Review
- Emerging roles for myeloid immune cells in bone metastasis.Cancer metastasis reviews · 2021Review
- Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression.Cancer medicine · 2020Article
- Platelets and Metastasis: New Implications of an Old Interplay.Frontiers in oncology · 2020Review
- Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice.Blood advances · 2019Article
- Review
- Bone Metastasis: Find Your Niche and Fit in.Trends in cancer · 2019Review
- Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis.British journal of pharmacology · 2018Review
- Translational models of prostate cancer bone metastasis.Nature reviews. Urology · 2018Review
- Osteoblasts Are the Centerpiece of the Metastatic Bone Microenvironment.Endocrinology and metabolism (Seoul, Korea) · 2016Review
- The role of platelets and megakaryocytes in bone metastasis.Journal of bone oncology · 2016Article
- Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis.American journal of cancer research · 2015Article
- Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.Cancer metastasis reviews · 2014Review
- Article
- Blood clot formation does not affect metastasis formation or tumor growth in a murine model of breast cancer.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer cells commonly spread through the circulation, but few successfully generate metastatic foci in bone. Osteoclastic cellular activity has been proposed as an initiating event for skeletal metastasis. Megakaryocytes (MKs) inhibit osteoclastogenesis, which could have an impact on tumor establishment in bone. Given the location of mature MKs at vascular sinusoids, they may be the first cells to physically encounter cancer cells as they enter the bone marrow. Identification of the interaction between MKs and prostate cancer cells was the focus of this study. K562 (human MK precursors) and primary MKs derived from mouse bone marrow hematopoietic precursor cells potently suppressed prostate carcinoma PC-3 cells in coculture. The inhibitory effects were specific to prostate carcinoma cells and were enhanced by direct cell-cell contact. Flow cytometry for propidium iodide (PI) and annexin V supported a proapoptotic role for K562 cells in limiting PC-3 cells. Gene expression analysis revealed reduced mRNA levels for cyclin D1, whereas mRNA levels of apoptosis-associated specklike protein containing a CARD (ASC) and death-associated protein kinase 1 (DAPK1) were increased in PC-3 cells after coculture with K562 cells. Recombinant thrombopoietin (TPO) was used to expand MKs in the marrow and resulted in decreased skeletal lesion development after intracardiac tumor inoculation. These novel findings suggest a potent inhibitory role of MKs in prostate carcinoma cell growth in vitro and in vivo. This new finding, of an interaction of metastatic tumors and hematopoietic cells during tumor colonization in bone, ultimately will lead to improved therapeutic interventions for prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.